Articles

Orthostatic intolerance syndromes after hematopoietic cell transplantation: clinical characteristics and therapeutic interventions in a single-center experience

Hematopoietic cell transplantation (HCT) is an established and potentially curative therapeutic option for hematologic cancers. HCT survivors are at risk of developing long-term complications impacting on morb...

Authors: Alessandra Vecchié, Georgia Thomas, Edoardo Bressi, Aldo Bonaventura, Justin M. Canada, David Chuquin, Dinesh Kadariya, Usman Piracha, Delia Endicott, Roshanak Markley, Amir Toor, Michael Hess and Antonio Abbate

Differentiation syndrome-induced Myopericarditis in the induction therapy of acute Promyelocytic leukemia: a case report

All trans retinoic acid (ATRA) has revolutionized the treatment and outcomes of patients with Acute Promyelocytic Leukemia (APL). Induction therapy with ATRA is associated with the rare but potentially fatal c...

Authors: Shabari Mangalore Shenoy, Thomas Di Vitantonio, Anna Plitt, Rocio Perez-Johnston, Jillian Gutierrez, David A. Knorr, Eytan M. Stein, Jennifer E. Liu and Stephanie Feldman

Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib

Ibrutinib is a Bruton’s tyrosine kinase inhibitor used in the treatment of hematological malignancies. The most common cardiotoxicity associated with ibrutinib is atrial arrhythmia (atrial fibrillation and flu...

Authors: Juan Carlo Avalon, Jacob Fuqua, Tyler Miller, Seth Deskins, Chelby Wakefield, Austin King, Sonya Inderbitzin-Brooks, Christopher Bianco, Lauren Veltri, Wei Fang, Michael Craig, Abraham Kanate, Kelly Ross, Midhun Malla and Brijesh Patel

Increased risk of non-hematological cancer in young patients with aortic stenosis: a retrospective cohort study

We have previously reported an increased risk for non-hematological malignancies in young patients with moderate or severe aortic stenosis (AS). These findings were the result of a post-hoc analysis from a lar...

Authors: Walid Saliba, Tamir Bental, Yaron Shapira, Shmuel Schwartzenberg, Alex Sagie, Moti Vaturi, Salim Adawi, Alexander Fuks, Ami Aronheim and Avinoam Shiran

Acute cardiotoxicity after initiation of the novel tyrosine kinase inhibitor gilteritinib for acute myeloid leukemia

Gilteritinib is a novel FMS-like tyrosine kinase 3 inhibitor recently approved by the United States Food and Drug Administration in 2018 for relapsed or refractory acute myeloid leukemia. However, gilteritinib...

Authors: Lisa Kim, Brian Fowler, Courtney M. Campbell, Jeremy Slivnick, Haseeb Nawaz, Yaquta Kaka, Patrick Ruz, Ajay Vallakati, Ragavendra Baliga, Sumithira Vasu and Daniel Addison

Sacubitril/valsartan is well tolerated in patients with longstanding heart failure and history of cancer and improves ventricular function: real-world data

Sacubitril/valsartan has been shown to significantly reduce cardiovascular mortality and hospitalizations due to heart failure in patients with reduced ejection fraction (HFrEF) when compared to enalapril. Dat...

Authors: Maria Klara Frey, Henrike Arfsten, Noemi Pavo, Emilie Han, Stefan Kastl, Martin Hülsmann, Mariann Gyöngyösi and Jutta Bergler-Klein

Cisplatin, environmental metals, and cardiovascular disease: an urgent need to understand underlying mechanisms

Significantly increased risks of cardiovascular disease occur in testicular cancer survivors given cisplatin-based chemotherapy. The postulated mechanism of platinum-based chemotherapy’s vascular toxicity has ...

Authors: Suparna C. Clasen, Paul C. Dinh Jr, Lifang Hou, Chunkit Fung, Howard D. Sesso and Lois B. Travis

Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial

Recent advances in the treatment algorithms of early breast cancer have markedly improved overall survival. However, anthracycline- and trastuzumab-associated cardiotoxicity may lead to dose-reduction or halt ...

Authors: A Mecinaj, G Gulati, SL Heck, E Holte, MW Fagerland, AI Larsen, E.S Blix, J Geisler, T Wethal and T Omland

Palliative care referral criteria and outcomes in cancer and heart failure: a systematic review of literature

Cardiotoxicity resulting in heart failure (HF) is among the most dreaded complications of cancer therapy and can significantly impact morbidity and mortality. Leading professional societies in cardiology and o...

Authors: Anecita P. Fadol, Ashley Patel, Valerie Shelton, Kate J. Krause, Eduardo Bruera and Nicolas L. Palaskas

Vasospastic angina in a chronic myeloid leukemia patient treated with nilotinib

Nilotinib, a second-generation BCR-ABL tyrosine kinase inhibitor (TKI), is highly effective in the treatment of patients with chronic myeloid leukemia (CML), despite being more vasculotoxic than older TKIs suc...

Authors: Shunsuke Maruta, Kyohei Usami, Kazuko Tajiri, Masafumi Otani, Daigo Hiraya, Hiroaki Watabe, Tomoya Hoshi, Akira Sato and Masaki Ieda

Rationale and proposed framework for shared decision making in cardio-oncology

Physicians have a duty to present diagnostic and therapeutic choices with rational guidance that respects patient values and realizes patient goals. In cardio-oncology, we commonly encounter patients who under...

Authors: Sarah C. Hull, Aaron Soufer, Erica S. Spatz and Lauren A. Baldassarre

Small cell carcinoma presenting as a biatrial mass with obstructive physiology: a case report

Small cell carcinoma is a highly aggressive and often fatal cancer that most commonly arises in the lung, although it can occasionally arise from other sites, such as the gastrointestinal tract, prostate or ce...

Authors: Sara Ratican, Soomin Shin and John Moretto

Impact of cancer and cardiovascular disease on in-hospital outcomes of COVID-19 patients: results from the american heart association COVID-19 cardiovascular disease registry

While pre-existing cardiovascular disease (CVD) appears to be associated with poor outcomes in patients with Coronavirus Disease 2019 (COVID-19), data on patients with CVD and concomitant cancer is limited. Th...

Authors: David M. Tehrani, Xiaoyan Wang, Asim M. Rafique, Salim S. Hayek, Joerg Herrmann, Tomas G. Neilan, Pooja Desai, Alicia Morgans, Juan Lopez-Mattei, Rushi V. Parikh and Eric H. Yang

Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases

Immune checkpoint inhibitor (ICI) induced myocarditis is a rare, severe, and often fatal adverse event. Evidence to guide appropriate immunosuppressive therapy is scarce. We present a case of ICI-induced myoca...

Authors: Emma Matzen, Lars Erik Bartels, Brian Løgstrup, Stine Horskær, Christina Stilling and Frede Donskov

Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review

The emergence of immune checkpoint inhibitors (ICIs) has brought about a paradigm shift in cancer treatment as the use of these drugs has become more frequent and for a longer duration. As a result of T-cell-m...

Authors: Shingo Kazama, Ryota Morimoto, Yuki Kimura, Naoki Shibata, Reina Ozaki, Takashi Araki, Takashi Mizutani, Hideo Oishi, Yoshihito Arao, Tasuku Kuwayama, Hiroaki Hiraiwa, Toru Kondo, Kenji Furusawa, Tomoya Shimokata, Takahiro Okumura, Yasuko K. Bando…

TAVR and cancer: machine learning-augmented propensity score mortality and cost analysis in over 30 million patients

Cardiovascular disease (CVD) and cancer are the top mortality causes globally, yet little is known about how the diagnosis of cancer affects treatment options in patients with hemodynamically compromising aort...

Authors: Dominique J. Monlezun, Logan Hostetter, Prakash Balan, Nicolas Palaskas, Juan Lopez-Mattei, Mehmet Cilingiroglu, Zaza Iakobishvili, Michael Ewer, Konstantinos Marmagkiolis and Cezar Iliescu

A new classification of cardio-oncology syndromes

Increasing evidence suggests a multifaceted relationship exists between cancer and cardiovascular disease (CVD). Here, we introduce a 5-tier classification system to categorize cardio-oncology syndromes (COS) ...

Authors: Rudolf A. de Boer, Joseph Pierre Aboumsallem, Valentina Bracun, Douglas Leedy, Richard Cheng, Sahishnu Patel, David Rayan, Svetlana Zaharova, Jennifer Rymer, Jennifer M. Kwan, Joshua Levenson, Claudio Ronco, Paaladinesh Thavendiranathan and Sherry-Ann Brown

Early detection of myocardial changes with and without dexrazoxane using serial magnetic resonance imaging in a pre-clinical mouse model

Cancer therapy-related cardiac dysfunction may occur in pediatric cancer survivors. Identification of early markers of myocardial damage secondary to anthracycline exposure is crucial to develop strategies tha...

Authors: Cory V. Noel, Nino Rainusso, Matthew Robertson, Jonathan Romero, Prakash Masand, Cristian Coarfa and Robia Pautler

Patient reported physical and mental health changes associated with a comprehensive cardiovascular risk reduction program for women with breast cancer receiving potentially cardiotoxic chemotherapy

Women with breast cancer (BCA) and cardiovascular disease (CVD) risk factors are at increased risk of developing cardiovascular complications when exposed to potentially cardiotoxic cancer therapy. The benefit...

Authors: Michael G. Fradley, Mohammed Alomar, Marcus W. Kilpatrick, Bernadette Shields, Nhi Tran, Amey Best, Erika Bianco, Merna Armanious, R. Ashton Vautier, Kevin Kip, Theresa M. Beckie and Roohi Ismail-Khan

Metastatic colorectal carcinoma to the right atrium: a case report and review of the literature

Cardiac metastasis due to colon cancer is extraordinarily uncommon. Given the rarity of diagnosis, there is paucity of evidence and hence, no established guidelines for evaluation or clinical management strategy.

Authors: Humaira Sarfraz, Abeer Arain, Mukul K. Divatia, Mary R. Schwartz and Kirk E. Heyne

Evidence-based prediction and prevention of cardiovascular morbidity in adults treated for cancer

Cancer treatment-related morbidity relevantly compromises health status in cancer survivors, and efforts to optimise health-related outcomes in this population are vital to maximising healthy survivorship. A p...

Authors: Renske Altena, Laila Hubbert, Narsis A. Kiani, Yvonne Wengström, Jonas Bergh and Elham Hedayati

A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors

Modern therapies in oncology have increased cancer survivorship, as well as the incidence of cardiovascular adverse events. While immune checkpoint inhibitors have shown significant clinical impact in several ...

Authors: Jessica Castrillon Lal, Sherry-Ann Brown, Patrick Collier and Feixiong Cheng

Lower endothelium-dependent microvascular function in adult breast cancer patients receiving radiation therapy

Cancer patients with a history of radiotherapy are at an increased risk of ischemic heart disease. Preclinical animal studies demonstrate markedly impaired acetylcholine (ACh)-mediated endothelium-dependent va...

Authors: Heather R. Banister, Stephen T. Hammond, Shannon K. Parr, Shelbi L. Sutterfield, Vanessa-Rose G. Turpin, Scott Treinen, Martin J. Bell and Carl J. Ade

CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin

The CBR3 V244M single nucleotide polymorphism has been linked to the risk of anthracycline-related cardiomyopathy in survivors of childhood cancer. There have been limited prospective studies examining the impact...

Authors: Jennifer K. Lang, Badri Karthikeyan, Adolfo Quiñones-Lombraña, Rachael Hageman Blair, Amy P. Early, Ellis G. Levine, Umesh C. Sharma, Javier G. Blanco and Tracey O’Connor

Both intermuscular fat and LVEF decline promote heart failure symptoms in cancer survivors

Approximately 20% of cancer survivors treated with chemotherapy experience worsening heart failure (HF) symptoms post-cancer treatment. While research has predominantly investigated the role of cardiotoxic tre...

Authors: Kerryn W. Reding, Nathaniel S. O’Connell, Ralph B. D’Agostino Jr, William Hundley, Alexander R. Lucas, Amy C. Ladd, Jennifer H. Jordan, Emily M. Heiston, Yaorong Ge and W. Gregory Hundley

Damage to cardiac vasculature may be associated with breast cancer treatment-induced cardiotoxicity

Breast cancer is the most common female cancer worldwide. Effective therapies including doxorubicin and trastuzumab have improved survival, but are associated with a substantial risk of cardiovascular disease....

Authors: Rebecca K. Hoffman, Bang-Jin Kim, Payal D. Shah, Joseph Carver, Bonnie Ky and Sandra Ryeom

Etiology and management of hypertension in patients with cancer

The pathophysiology of hypertension and cancer are intertwined. Hypertension has been associated with an increased likelihood of developing certain cancers and with higher cancer-related mortality. Moreover, v...

Authors: Turab Mohammed, Meghana Singh, John G. Tiu and Agnes S. Kim

Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Infliximab: a case series

Glucocorticoid treatment remains the cornerstone of therapy for immune checkpoint inhibitor (ICI) myocarditis, but data supporting the use of additional immunotherapy for steroid refractory cases remains limit...

Authors: Robert S. Zhang, Allison Padegimas, Kathleen M. Murphy, Peter T. Evans, Carli J. Peters, Christopher M. Domenico, Mahesh K. Vidula, Paul J. Mather, Marisa Cevasco, Roger B. Cohen, Joseph R. Carver and Rupal P. O’Quinn

Management strategies and clinical outcomes in breast cancer patients who develop left ventricular dysfunction during trastuzumab therapy

Trastuzumab reduces risk of breast cancer recurrence but carries risk of cardiotoxicity that may be reversible upon treatment cessation and institution of left ventricular (LV) enhancement therapies (LVETx). W...

Authors: Ren Jie Robert Yao, Jordan Gibson, Christine Simmons and Margot K. Davis

Insurance disparity in cardiovascular mortality among non-elderly cancer survivors

Insurance status plays a vital role in cancer diagnosis, treatments and survival. Cancer patients have higher cardiovascular disease (CVD) mortality than the general population.

Authors: Tiantian Shi, Changchuan Jiang, Cenjing Zhu, Fangcheng Wu, Irma Fotjhadi and Stuart Zarich

Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center

Immune checkpoint inhibitors (ICIs) are a novel class of anticancer agents that have demonstrated clinical response for both solid and hematological malignancies. ICIs are associated with development of immune...

Authors: Nida Waheed, Michael G. Fradley, David L. DeRemer, Ahmad Mahmoud, Chintan P. Shah, Taimour Y. Langaee, Gloria P. Lipori, Keith March, Carl J. Pepine, Rhonda M. Cooper-DeHoff, Yonghui Wu and Yan Gong

Risk of malignancy long after acute coronary syndrome in selected urban and rural areas and comparison with smoking risk: the ABC-7* study on Heart Disease

Increased cancer risk has been reported in patients with acute coronary syndrome (ACS).

Authors: Giuseppe Berton, Heba T. Mahmoud, Rosa Palmieri, Fiorella Cavuto, Rocco Cordiano, Elisabetta Lorenzon and Francesco Bagato

Competing mortality risks: predicted cardiovascular disease risk versus predicted risk of breast cancer mortality in patients receiving adjuvant chemotherapy in a single Irish center

Due to advances in care, most women diagnosed with breast cancer do not die from the disease itself. Instead, cardiovascular disease (CVD) remains the most frequent cause of death. Many breast cancer patients ...

Authors: Lisa Prior, Hannah Featherstone, David O’Reilly, Killian Nugent, Marvin Lim, John McCaffrey, Michaela J Higgins and Catherine M. Kelly

High intensity exercise during breast cancer chemotherapy - effects on long-term myocardial damage and physical capacity - data from the OptiTrain RCT

Adjuvant systemic breast cancer treatment improves disease specific outcomes, but also presents with cardiac toxicity. In this post-hoc exploratory analysis of the OptiTrain trial, the effects of exercise on c...

Authors: Josefin Ansund, Sara Mijwel, Kate A. Bolam, Renske Altena, Yvonne Wengström, Eric Rullman and Helene Rundqvist

Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma

Cardiovascular toxicity is a notorious complication of doxorubicin (DXR) therapy for diffuse large B-cell lymphoma (DLBCL). Although surveillance of well-known biological markers for cardiovascular disease (CV...

Authors: Charlott Mörth, Amal Abu Sabaa, Eva Freyhult, Christina Christersson, Jamileh Hashemi, Nashmil Hashemi, Masood Kamali-Moghaddam, Daniel Molin, Martin Höglund, Anna Eriksson and Gunilla Enblad

Echocardiographic myocardial strain analysis describes subclinical cardiac dysfunction after craniospinal irradiation in pediatric and young adult patients with central nervous system tumors

Craniospinal irradiation (CSI) is part of the treatment of central nervous system (CNS) tumors and is associated with cardiovascular disease in adults. Global myocardial strain analysis including longitudinal ...

Authors: Hugo R. Martinez, Ralph Salloum, Erin Wright, Lauren Bueche, Philip R. Khoury, Justin T. Tretter and Thomas D. Ryan

Baseline global longitudinal strain predictive of anthracycline-induced cardiotoxicity

Cancer therapy-related cardiac dysfunction (CTRD) is a major source of morbidity and mortality in long-term cancer survivors. Decreased GLS predicts decreased left ventricular ejection fraction (LVEF) in patie...

Authors: Raquel Araujo-Gutierrez, Kalyan R. Chitturi, Jiaqiong Xu, Yuanchen Wang, Elizabeth Kinder, Alpana Senapati, L. Bindu Chebrolu, Mahwash Kassi and Barry H. Trachtenberg

Healthcare disparities in cardio oncology: patients receive same level of surveillance regardless of race at a safety net hospital

Cardiotoxicity remains a dreaded complication for patients undergoing chemotherapy with human epidermal growth factor (HER)-2 receptor antagonists and anthracyclines. Though many studies have looked at racial ...

Authors: Crystal B. Chen, Raj K. Dalsania and Eman A. Hamad

A virtual-hybrid approach to launching a cardio-oncology clinic during a pandemic

As cardiovascular disease is a leading cause of death in cancer survivors, the new subspecialty of Cardio-Oncology has emerged to address prevention, monitoring, and management of cardiovascular toxicities to ...

Authors: Sherry-Ann Brown, Sahishnu Patel, David Rayan, Svetlana Zaharova, Mingqian Lin, Tarek Nafee, Bipin Sunkara, Ragasnehith Maddula, James MacLeod, Krishna Doshi, Joshua Meskin, David Marks and Jorge Saucedo

Book review: cancer and the heart

Authors: Umesh C. Sharma and Saraswati Pokharel

A case report: rapid progression of coronary atherosclerosis in a patient taking Targretin (Bexarotene)

Anti-neoplastic drugs have made major advancements in oncology, however they are not without cardiovascular consequences. We present a patient with cutaneous T-cell lymphoma receiving Targretin therapy who pre...

Authors: Sean DeAngelo, Kailyn I. Mann, Muhammad Abdulbasit, Amy Ahnert and Deborah W. Sundlöf

Takotsubo syndrome induced by brachytherapy in a patient with endocervical adenocarcinoma

Takotsubo syndrome (TTS), also known as stress cardiomyopathy, apical ballooning syndrome and broken heart syndrome, is characterized by acute-onset chest pain, electrocardiographic (ECG) abnormalities and rev...

Authors: Aline Cristini Vieira, Mauricio Fernando Silva Almeida Ribeiro, Julianne Lima, Jacob Sessim Filho, Heloisa de Andrade Carvalho and Max Senna Mano

The prevalence of iron deficiency and anemia and their impact on survival in patients at a cardio-oncology clinic

Iron deficiency (ID) and anemia are common in both heart failure (HF) and cancer patients and are associated with poor quality of life and survival. The aims of this study were (1) to evaluate the prevalence, ...

Authors: E. Čiburienė, J. Čelutkienė, S. Aidietienė, G. Ščerbickaitė and A. R. Lyon

Perspectives on the COVID-19 pandemic impact on cardio-oncology: results from the COVID-19 International Collaborative Network survey

Re-allocation of resources during the COVID-19 pandemic has resulted in delays in care delivery to patients with cardiovascular disease and cancer. The ability of health care providers to provide optimal care ...

Authors: Diego Sadler, Jeanne M. DeCara, Joerg Herrmann, Anita Arnold, Arjun K. Ghosh, Husam Abdel-Qadir, Eric H. Yang, Sebastian Szmit, Nausheen Akhter, Monika Leja, Carolina Maria Pinto Domingues Carvalho Silva, Jayant Raikhelkar, Sherry-Ann Brown, Susan Dent, Rupal O’Quinn, Franck Thuny…

Aerobic and resistance exercise improves Reynolds risk score in overweight or obese breast cancer survivors

Breast cancer survivors have double the risk of mortality from cardiovascular disease than age-matched women without a cancer history. Reynolds risk score (RRS) is a validated algorithm for the assessment of c...

Authors: Kyuwan Lee, Nathalie Sami, Debu Tripathy, Wendy Demark-Wahnefried, Mary K. Norris, Kerry S. Courneya and Christina M. Dieli-Conwright

Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer

Trastuzumab-induced cardiotoxicity (TIC) can lead to early discontinuation of adjuvant therapy, however there is limited evidence on long-term survival outcomes in patients with operable human epidermal growth...

Authors: Sagar Sardesai, Jasmine Sukumar, Mahmoud Kassem, Marilly Palettas, Julie Stephens, Evan Morgan, Daniel Addison, Ragavendra Baliga, Daniel G. Stover, Jeffrey VanDeusen, Nicole Williams, Mathew Cherian, Maryam Lustberg, Robert Wesolowski and Bhuvaneswari Ramaswamy

In ®Entresto we trust

Sacubitril/Valsartan (S/V) is a novel and remarkably effective opportunity to treat heart failure with reduced ejection fraction (HFrEF). However, patients with HFrEF induced by cancer therapy were a priori ex...

Authors: Massimiliano Camilli, Marco Giuseppe Del Buono, Pierantonio Menna and Giorgio Minotti

Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy

Cancer therapy-related cardiac dysfunction (CTRCD) is a critical problem with an impact on both oncological and cardiovascular prognosis, especially when it prevents patients from receiving cancer treatment. S...

Authors: Vanesa Gregorietti, Teresa Lopez Fernandez, Diego Costa, Elías Ortega Chahla and Andrés J. Daniele

Early- and late anthracycline-induced cardiac dysfunction: echocardiographic characterization and response to heart failure therapy

Anthracycline-induced cardiac dysfunction (ACD) is a notorious side effect of anticancer treatment. It has been described as a phenomenon of a continuous progressive decline of cardiac function, eventually lea...

Authors: Janine A. M. Kamphuis, Marijke Linschoten, Maarten J. Cramer, Pieter A. Doevendans, Folkert W. Asselbergs and Arco J. Teske

A case of irreversible bradycardia after rituximab therapy for diffuse large B-cell lymphoma

This is a case of a middle-aged woman with underlying cardiac conduction system with episodes of AV Wenckebach, who subsequently developed significant AV conduction system abnormalities after receiving one sta...

Authors: Nway Le Ko Ko, Nareg Minaskeian and Hicham Z. El Masry